BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Titan Spine Receives Regulatory Clearance to Launch Endoskeleton® TO PLIF and Oblique Interbody Fusion Devices


11/17/2010 7:46:39 AM

MEQUON, Wis.--(BUSINESS WIRE)--Titan Spine, a developer of novel interbody fusion implants, announced today that it has received FDA clearance to commercially release its Endoskeleton® TO system, which consists of a line of interbody devices placed through a Posterior Lumbar Interbody Fusion (PLIF) approach. The company plans to commercially release the product beginning in December, 2010.

Dr. Gerard Girasole, Orthopaedic Surgeon at the Orthopaedic & Sports Medicine Center in Trumbull, CT, is very pleased with the announcement. “The launch of the Endoskeleton® TO is a significant milestone in the evolution of the Titan Spine product pipeline,” said Dr. Girasole. “The PLIF/Oblique design is a perfect complement to the company’s previously-released TLIF system and offers a viable option to spine surgeons that prefer a posterior approach to interbody fusion. I fully expect to achieve the same type of clinical outcomes with the Endoskeleton® TO that I have been enjoying with Titan’s other interbody constructs.”

This is the fourth regulatory clearance for the company. “The Endoskeleton® TO incorporates the same innovative design features of our commercially-available cervical, ALIF and TLIF devices – a unique roughened Titanium surface that participates in the fusion process,” commented Chad Patterson, Director of Product Development and Operations for Titan Spine. “We chose to use Titanium due to its affinity to integrate with bone and its track record of success in other orthopedic applications. We feel the design and composition of our implants help to promote earlier bony ingrowth and stability in comparison to other available materials, thus leading to improved outcomes for our patients.”

About Titan Spine - Titan Spine, LLC is a privately owned company in Mequon, Wisconsin focusing on the design and manufacturing of bioactive interbody fusion devices for the spine. Founded in 2005, the company is committed to developing advanced products for treatment of various pathologies that cause back pain.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES